![](/img/cover-not-exists.png)
What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia
Karnon, Jonathan, Shafie, Ainul Shakirah, Orji, Nneka, Usman, Sofoora KawsarVolume:
14
Language:
english
Journal:
Cost Effectiveness and Resource Allocation
DOI:
10.1186/s12962-016-0060-5
Date:
December, 2016
File:
PDF, 910 KB
english, 2016